Background: To examine the efficacy and safety of an intravitreal cell-based production of glucagon-like peptide-1 (GLP-1) by intravitreally implanted and encapsulated cells.
Methods: The experimental study included 12 Sprague-Dawley rats. Four cell beads with a diameter of 600 μm were intravitreally implanted. Each bead contained 3,000 GLP-1-secreting cells, which were encapsulated by a barium cross-linked sodium alginate matrix. At baseline and at each of the follow-up examinations at Day 3, Day 7, and Day 14, 4, 3, 3, and 2 animals, respectively, were killed. The concentration of active GLP-1 in the vitreous body samples was determined by enzyme-linked immunosorbent assay. The retinas were histologically examined.
Results: The active GLP-1 concentration in the vitreous samples increased significantly after baseline (<5 pM) to a peak at Day 3 (287 ± 196 pM) and at Day 7 (238 ± 55 pM), before it decreased at Day 14 (70 ± 8 pM). The histologic examinations did not show signs of apoptosis or tissue destruction.
Conclusion: The intravitreal application of beads containing alginate-encapsulated cells producing GLP-1 resulted in an intraocular production of GLP-1 with a significant increase in the intraocular GLP-1 concentration, without observed cytotoxic effects. An intravitreal cell-based drug therapy with GLP-1 appears feasible.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/IAE.0b013e3181f27509 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nonclinical Similarity of the Biosimilar Candidate ABP 938 with Aflibercept Reference Product.
Ophthalmol Ther
January 2025
Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320-1799, USA.
Introduction: ABP 938 is being developed as a biosimilar to Eylea (aflibercept reference product [RP]), an anti-vascular endothelial growth factor (VEGF) drug used in the management of retinal diseases. Previously, a comparative analytical similarity assessment demonstrated that ABP 938 and aflibercept RP have the same amino acid sequence and exhibit similar higher-order structure and biological activity. The nonclinical studies described here were designed to assess the in vitro pharmacology and the in vivo pharmacokinetics (PK), toxicokinetics (TK), and safety profiles of ABP 938 compared to aflibercept RP.
View Article and Find Full Text PDFHydrogels in Ophthalmology: Novel Strategies for Overcoming Therapeutic Challenges.
Materials (Basel)
December 2023
Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, QC H3A 1G1, Canada.
Article Synopsis
- The intricate design of the human eye requires specialized approaches for treating eye diseases, leading to recent interest in hydrogels as a therapeutic option.
- Hydrogels have been highlighted for their benefits in drug delivery to the back of the eye and in enhancing intraocular lens technology over the past five years.
- Although hydrogels show great promise for targeted drug release and improved patient outcomes, most studies are still in preclinical stages, necessitating thorough clinical evaluations before widespread use.
HLA-Homozygous iPSC-Derived Mesenchymal Stem Cells Rescue Rotenone-Induced Experimental Leber's Hereditary Optic Neuropathy-like Models In Vitro and In Vivo.
Cells
November 2023
Department of Medical Research, Taipei Veterans General Hospital, Taipei 112201, Taiwan.
Background: Mesenchymal stem cells (MSCs) hold promise for cell-based therapy, yet the sourcing, quality, and invasive methods of MSCs impede their mass production and quality control. Induced pluripotent stem cell (iPSC)-derived MSCs (iMSCs) can be infinitely expanded, providing advantages over conventional MSCs in terms of meeting unmet clinical demands.
Methods: The potential of MSC therapy for Leber's hereditary optic neuropathy (LHON) remains uncertain.
Suprachoroidal Injection: A Novel Approach for Targeted Drug Delivery.
Pharmaceuticals (Basel)
September 2023
Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, QC H3A 1G1, Canada.
Treating posterior segment and retinal diseases poses challenges due to the complex structures in the eye that act as robust barriers, limiting medication delivery and bioavailability. This necessitates frequent dosing, typically via eye drops or intravitreal injections, to manage diseases, often leading to side effects with long-term use. Suprachoroidal injection is a novel approach for targeted drug delivery to the posterior segment.
View Article and Find Full Text PDFTherapeutic Extracellular Vesicles from Tonsil-Derived Mesenchymal Stem Cells for the Treatment of Retinal Degenerative Disease.
Tissue Eng Regen Med
October 2023
Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, 13620, Korea.
Background: Retinal degenerative disease (RDD), one of the most common causes of blindness, is predominantly caused by the gradual death of retinal pigment epithelial cells (RPEs) and photoreceptors due to various causes. Cell-based therapies, such as stem cell implantation, have been developed for the treatment of RDD, but potential risks, including teratogenicity and immune reactions, have hampered their clinical application. Stem cell-derived extracellular vesicles (EVs) have recently emerged as a cell-free alternative therapeutic strategy; however, additional invasiveness and low yield of the stem cell extraction process is problematic.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!